{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T12:32:40Z","timestamp":1767184360195,"version":"build-2238731810"},"reference-count":33,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_dmpt-2020-0139_abs_001_w2aab3b7c28b1b6b1aab1c15b1Aa\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the serum dosage of the biomedicine (DBM) and the incidence of antidrug antibody (ADA) against antitumor necrosis factor (TNF) in spondyloarthritis, and to demonstrate the influence of these parameters on the clinical efficiency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmpt-2020-0139_abs_002_w2aab3b7c28b1b6b1aab1c15b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional multicentric study including patients with spondylarthritis (SpA) under antiTNF (infliximab [INF], etanercept [ETA] and adalimumab [ADL]) for at least 6\u00a0months. A dosage of the ADA and DBM were practiced by the immuno-enzymatic essay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmpt-2020-0139_abs_003_w2aab3b7c28b1b6b1aab1c15b3Aa\">\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>Seventy one patients were recruited. Disease modifying antirheumatic drugs (DMARDs) were associated with anti-TNF in 30%. ADA was positive in 54% for INF, 33% for ADL and 0% for ETA with a significant difference(p&lt;0.0001). Immunogenicity was correlated to a bad therapeutic response (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]\u22654)(p=0.04). The DBM was inversely correlated with the rate of ADA for patients treated with INF(p&lt;0.0001) and ADL(p&lt;0.0001). The DBM was also inversely correlated with BASDAI of INF(p=0.03) and ADL (p=0.01). ADA was significantly associated with an anterior switch of anti TNF(p=0.04), the use of INF(p=0.002), presence of coxitis(p=0.01) and higher body mass index (BMI)(p=0.007). DMARDs associated with anti TNF were not a protective factor for positive ADA. In a multivariate study, only INF and BMI were independent factors of positive ADA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmpt-2020-0139_abs_004_w2aab3b7c28b1b6b1aab1c15b4Aa\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The ADA formation lowered the DBM and favored the therapeutic failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/dmpt-2020-0139","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T09:56:56Z","timestamp":1657879016000},"page":"25-32","source":"Crossref","is-referenced-by-count":2,"title":["Immunogenicity of antitumor necrosis factor therapy in patients with spondyloarthritis"],"prefix":"10.1515","volume":"36","author":[{"given":"Ines","family":"Mahmoud","sequence":"first","affiliation":[{"name":"Doctor in the Department of Rheumatology , Charles Nicolle Hospital , Tunis , Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4623-6284","authenticated-orcid":false,"given":"Leila","family":"Rouached","sequence":"additional","affiliation":[{"name":"Doctor in the Department of Rheumatology , Charles Nicolle Hospital , Tunis , Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aicha","family":"Ben Tekaya","sequence":"additional","affiliation":[{"name":"Doctor in the Department of Rheumatology , Charles Nicolle Hospital , Tunis , Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olfa","family":"Saidane","sequence":"additional","affiliation":[{"name":"Doctor in the Department of Rheumatology , Charles Nicolle Hospital , Tunis , Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma","family":"Bouden","sequence":"additional","affiliation":[{"name":"Doctor in the Department of Rheumatology , Charles Nicolle Hospital , Tunis , Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saoussen","family":"Jradi","sequence":"additional","affiliation":[{"name":"Doctor in the Department of Rheumatology , Charles Nicolle Hospital , Tunis , Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imen","family":"Sfar","sequence":"additional","affiliation":[{"name":"Doctor in Department of Immunology , Charles Nicolle Hospital , Tunis , Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rawdha","family":"Tekaya","sequence":"additional","affiliation":[{"name":"Doctor in the Department of Rheumatology , Charles Nicolle Hospital , Tunis , Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kawther","family":"Ben Abdelghani","sequence":"additional","affiliation":[{"name":"Doctor in the Department of Rheumatology , Mongi Slim Hospital , Tunis , Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousr","family":"Lakhoua Gorgi","sequence":"additional","affiliation":[{"name":"Doctor in Department of Immunology , Charles Nicolle Hospital , Tunis , Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Abdelmoula","sequence":"additional","affiliation":[{"name":"Doctor in the Department of Rheumatology , Charles Nicolle Hospital , Tunis , Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"key":"2022071513542004488_j_dmpt-2020-0139_ref_001_w2aab3b7c28b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Moreland, LW, Baumgartner, SW, Schiff, MH, Tindall, EA, Fleischmann, RM, Weaver, AL, et al.. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141\u20137. https:\/\/doi.org\/10.1056\/nejm199707173370301.","DOI":"10.1056\/NEJM199707173370301"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_002_w2aab3b7c28b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Bartelds, GM, Krieckaert, CL, Nurmohamed, MT, van Schouwenburg, PA, Lems, WF, Twisk, JW, et al.. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. J Am Med Assoc 2011;305:1460\u20138. https:\/\/doi.org\/10.1001\/jama.2011.406.","DOI":"10.1001\/jama.2011.406"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_003_w2aab3b7c28b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"van Schouwenburg, PA, Rispens, T,Wolbink, GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013;9:164\u201372. https:\/\/doi.org\/10.1038\/nrrheum.2013.4.","DOI":"10.1038\/nrrheum.2013.4"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_004_w2aab3b7c28b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Garc\u00eas, S, Demengeot, J, Benito-Garcia, E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72:1947\u201355. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202220.","DOI":"10.1136\/annrheumdis-2012-202220"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_005_w2aab3b7c28b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Radstake, TR, Svenson, M, Eijsbouts, AM, van den Hoogen, FH, Enevold, C, van Riel, PL, et al.. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739\u201345. https:\/\/doi.org\/10.1136\/ard.2008.092833.","DOI":"10.1136\/ard.2008.092833"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_006_w2aab3b7c28b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Vincent, FB, Morand, EF, Murphy, K, Mackay, F, Mariette, X, Marcelli, C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72:165\u201378. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202545.","DOI":"10.1136\/annrheumdis-2012-202545"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_007_w2aab3b7c28b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Zhao, S, Mysler, E, Moots, RJ. Etanercept for the treatment of rheumatoid arthritis. Immunotherapy 2018;10:433\u201345. https:\/\/doi.org\/10.2217\/imt-2017-0155.","DOI":"10.2217\/imt-2017-0155"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_008_w2aab3b7c28b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Garc\u00eas, S, Demengeot, J, Benito-Garcia, E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72:1947\u201355. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202220.","DOI":"10.1136\/annrheumdis-2012-202220"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_009_w2aab3b7c28b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Braun, J, van den Berg, R, Baraliakos, X, Boehm, H, Burgos-Vargas, R, Collantes-Estevez, E, et al.. 2011Update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis (AS). Ann Rheum Dis 2010;70:896\u2013904.","DOI":"10.1136\/ard.2011.151027"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_010_w2aab3b7c28b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Balsa, A, Lula, S, Marshall, L, Szczypa, P, Aikman, L. The comparative immunogenicity of biologic therapy and it sclinical relevance in psoriatic arthritis: a systematic review of the literature. Expert OpinBiolTher 2018;18:575\u201384. https:\/\/doi.org\/10.1080\/14712598.2018.1450385.","DOI":"10.1080\/14712598.2018.1450385"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_011_w2aab3b7c28b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Mease, PJ, Kivitz, AJ, Burch, FX, Siegel, EL, Cohen, SB, Ory, P, et al.. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264\u201372. https:\/\/doi.org\/10.1002\/art.20335.","DOI":"10.1002\/art.20335"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_012_w2aab3b7c28b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Antoni, C, Krueger, GG, de Vlam, K, Birbara, C, Beutler, A, Guzzo, C, et al.. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150\u20137. https:\/\/doi.org\/10.1136\/ard.2004.032268.","DOI":"10.1136\/ard.2004.032268"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_013_w2aab3b7c28b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Anderson, P, Louie, J, Lau, A, Broder, M. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Curr Rheumatol Rep 2005;7:3\u20139. https:\/\/doi.org\/10.1007\/s11926-005-0002-2.","DOI":"10.1007\/s11926-005-0002-2"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_014_w2aab3b7c28b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Emi Aikawa, N, de Carvalho, JF, Artur Almeida Silva, C, Bonfa, E. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010;38:82\u20139. https:\/\/doi.org\/10.1007\/s12016-009-8140-3.","DOI":"10.1007\/s12016-009-8140-3"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_015_w2aab3b7c28b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Jung, SM, Kim, H-S, Kim, H-R, Kim, NY, Lee, J-H, Kim, J, et al.. Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis. IntImmunopharmacol 2014;21:20\u20135. https:\/\/doi.org\/10.1016\/j.intimp.2014.04.006.","DOI":"10.1016\/j.intimp.2014.04.006"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_016_w2aab3b7c28b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Kiely, PDW. Biologic efficacy optimization\u2014a step towards personalized medicine. Rheumatology. 2016;55:780\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kev356.","DOI":"10.1093\/rheumatology\/kev356"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_017_w2aab3b7c28b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Gremese, E, Carletto, A, Padovan, M, Atzeni, F, Raffeiner, B, Giardina, AR, et al.. Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res 2013;65:94\u2013100. https:\/\/doi.org\/10.1002\/acr.21768.","DOI":"10.1002\/acr.21768"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_018_w2aab3b7c28b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Jani, M, Chinoy, H, Warren, RB, Fu, B, Griffiths, CE, Morgan, AW, et al.. Influence of immunogenicity and drug levels on the efficacy of long-term treatment of rheumatoid arthritis with adalimumab and etanercept: a UK-based prospective study. Ann Rheum Dis 2014;73:i89\u201390. https:\/\/doi.org\/10.1136\/annrheumdis-2014-eular.3811.","DOI":"10.1136\/annrheumdis-2014-eular.3811"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_019_w2aab3b7c28b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Lorenz, HM, Behrens, F, Lippe, R, Jobst, J, L\u00f6schmann, PA, Meier, L. Etanercept as monotherapy or in combination with conventional DMARDs in psoriatic arthritis: results from a large prospective multicenter observational study. Ann Rheum Dis 2015;74 (Suppl\u00a02):THU0415.","DOI":"10.1136\/annrheumdis-2015-eular.2788"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_020_w2aab3b7c28b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Plasencia, C, Pascual-Salcedo, D, Nu\u00f1o, L, Bonilla, G, Villalba, A, Peiteado, D, et al.. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis 2012;71:1955\u201360. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200828.","DOI":"10.1136\/annrheumdis-2011-200828"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_021_w2aab3b7c28b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Murdaca, G, Negrini, S, Magnani, O, Penza, E, Pellecchio, M, Puppo, F. Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis. Expet Opin Drug Saf 2017;16:1173\u20139. https:\/\/doi.org\/10.1080\/14740338.2017.1361404.","DOI":"10.1080\/14740338.2017.1361404"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_022_w2aab3b7c28b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Morales-Lara, MJ, Ca\u00f1ete, JD, Torres-Moreno, D, Hern\u00e1ndez, MV, Pedrero, F, Celis, R, et al.. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Jt Bone Spine Rev Rhum 2012;79:591\u20136. https:\/\/doi.org\/10.1016\/j.jbspin.2012.02.003.","DOI":"10.1016\/j.jbspin.2012.02.003"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_023_w2aab3b7c28b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"de VriesMK, Wolbink, GJ, Stapel, SO, de Vrieze, H, van Denderen, JC, Dijkmans, BA, et al.. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007;66:1252\u20134. https:\/\/doi.org\/10.1136\/ard.2007.072397.","DOI":"10.1136\/ard.2007.072397"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_024_w2aab3b7c28b1b6b1ab2b2c24Aa","unstructured":"Bornstein, G, Lidar, M, Langevitz, P, Fardman, A, Ben-Zvi, I, Grossman, C. The prevalence and clinical effect of immunogenicity of TNF-\u03b1 blockers in patients with axial spondyloarthritis. Clin Exp Rheumatol 2018;36:228\u201332."},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_025_w2aab3b7c28b1b6b1ab2b2c25Aa","unstructured":"Arends, S, Lebbink, HR, Spoorenberg, A, Bungener, LB, Roozendaal, C, van der Veer, E, et al. The formation of autoantibodies and antibodies to TNF-\u03b1 blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010;28:661\u20138."},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_026_w2aab3b7c28b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"AIRE-MB Group, Senabre Gallego, JM, Rosas, J, Marco-Mingot, M, Garc\u00eda-G\u00f3mez, JA, Santos-Soler, G, et al.. Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis. Rheumatol Int 2019;39:841\u20139. https:\/\/doi.org\/10.1007\/s00296-019-04288-7.","DOI":"10.1007\/s00296-019-04288-7"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_027_w2aab3b7c28b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Kneepkens, EL, Wei, JC-C, Nurmohamed, MT, Yeo, K-J, Chen, CY, van der Horst-Bruinsma, IE, et al.. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24\u00a0weeks of follow-up. Ann Rheum Dis 2015;74:396\u2013401. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204185.","DOI":"10.1136\/annrheumdis-2013-204185"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_028_w2aab3b7c28b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Cludts, I, Spinelli, FR, Morello, F, Hockley, J, Valesini, G, Wadhwa, M. Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab. Cytokine 2017;96:16\u201323. https:\/\/doi.org\/10.1016\/j.cyto.2017.02.015.","DOI":"10.1016\/j.cyto.2017.02.015"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_029_w2aab3b7c28b1b6b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"de Vries, MK, Brouwer, E, van der Horst-Bruinsma, IE, Spoorenberg, A, van Denderen, JC, Jamnitski, A, et al.. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 2009;68:1787\u20138. https:\/\/doi.org\/10.1136\/ard.2009.109702.","DOI":"10.1136\/ard.2009.109702"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_030_w2aab3b7c28b1b6b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Koren, E, Smith, HW, Shores, E, Shankar, G, Finco-Kent, D, Rup, B, et al.. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 2008;333:1\u20139. https:\/\/doi.org\/10.1016\/j.jim.2008.01.001.","DOI":"10.1016\/j.jim.2008.01.001"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_031_w2aab3b7c28b1b6b1ab2b2c31Aa","doi-asserted-by":"crossref","unstructured":"Gorovits, B. Antidrug antibody assay validation: industry survey results. AAPS J 2009;11:133\u20138. https:\/\/doi.org\/10.1208\/s12248-009-9091-6.","DOI":"10.1208\/s12248-009-9091-6"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_032_w2aab3b7c28b1b6b1ab2b2c32Aa","doi-asserted-by":"crossref","unstructured":"Hart, MH, de VriezeH,WoutersD,Wolbink, GJ, Killestein, J, de Groot, ER, et al.. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011;372:196\u2013203. https:\/\/doi.org\/10.1016\/j.jim.2011.07.019.","DOI":"10.1016\/j.jim.2011.07.019"},{"key":"2022071513542004488_j_dmpt-2020-0139_ref_033_w2aab3b7c28b1b6b1ab2b2c33Aa","doi-asserted-by":"crossref","unstructured":"Aarden, L, Ruuls, SR, Wolbink, G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008;20:431\u20135. https:\/\/doi.org\/10.1016\/j.coi.2008.06.011.","DOI":"10.1016\/j.coi.2008.06.011"}],"container-title":["Drug Metabolism and Drug Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2020-0139\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2020-0139\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T10:00:34Z","timestamp":1657879234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2020-0139\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":33,"aliases":["10.1515\/dmdi-2020-0139"],"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,9,30]]},"published-print":{"date-parts":[[2021,3,30]]}},"alternative-id":["10.1515\/dmpt-2020-0139"],"URL":"https:\/\/doi.org\/10.1515\/dmpt-2020-0139","relation":{},"ISSN":["2191-0162","0792-5077"],"issn-type":[{"value":"2191-0162","type":"electronic"},{"value":"0792-5077","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,6]]}}}